国产人妖在线视频I午夜av一区二区三区I国产色一区二区I一级片视频在线观看I一级毛片儿I亚色图I丁香花一区二区I超碰97在线免费I久久精品中文字幕I日韩在线视频观看免费I无码中文字幕色专区I欧美专区亚洲专区I国产tv在线观看I2024最新黄色网址I日本老妇高潮乱hdI成人免费入口I日韩精品视频在线看I国产传媒在线播放I一本岛视频在线观看I自拍日韩亚洲一区在线I国产成人亚洲综合a∨婷婷I国产精品2019I色亚洲天堂Iav黄色免费I欧美大尺度视频

Self-delivery of photosensitizers and immunomodulators to tumor sites can improve photodynamic immunotherapy, but this strategy is still challenging. Here, Professor Li Shiying, Professor Yu Xiyong of Guangzhou Medical University and Associate Professor Cheng Hong of Southern Medical University jointly reported a self-delivery photoimmunostimulant (called iPS) for photodynamic sensitization tumor immunotherapy.

The carrier-free iPS is self-assembled through the non-covalent interaction between the photosensitizer Ce6 and NLG919, which avoids the toxicity and immunogenicity caused by excipients. After intravenous injection, iPS tends to passively accumulate in the tumor site to trigger powerful photodynamic therapy , induce immunogenic cell death , activate cytotoxic T lymphocytes  and initiate anti-tumor immune response. At the same time, the co-delivery of NLG919 inhibited the activation of indoleamine 2,3-dioxygenase 1  and reversed the immunosuppressive tumor microenvironment. The photodynamic sensitization immunotherapy based on iPS can effectively inhibit the growth of primary and distal tumors, and has low system toxicity, which has inspired the development of clinically transformable and self-deliverable nanomedicines for precise tumor treatment.

In this paper, self-delivery photoimmunostimulants  for photodynamic enhancement of tumor immunotherapy were prepared by self-assembly of photosensitizers Ce6 and NLG919. Due to hydrophobicity, π-π stacking and electrostatic interaction, self-assembled iPS has improved solubility, stability and biocompatibility. In addition, carrier-free iPS has a high drug loading rate, which can avoid potential immunogenicity. Interestingly, the powerful PDT treatment of iPS can not only trigger tumor cell apoptosis, but also trigger an ICD response by promoting the migration of calreticulin to the cell surface and the extracellular release of high-mobility group protein B1. Mature DCs will recruit and activate CTLs, realizing synergistic immunotherapy of primary and distal tumors. The co-delivery of NLG919 inhibited IDO-1 activation and Treg tumor invasion, thereby reversing the immunosuppressive tumor microenvironment.

This information is sourced from the Internet for academic exchanges. If there is any infringement, please contact us to delete it immediately